Cisplatin is a commonly used chemotherapeutic drugs. It is known for its nephrotoxic side effects with an increased risk of acute kidney injury. Finding of clinically feasible cisplatin nephrotoxicity markers is of importance. In our study, we compared neutrophil gelatinase-associated lipocalin (NGAL) in serum and urine, the estimated glomerular filtration rate (based on serum cystatin C) and urine albumin as markers of nephrotoxicity. The study involved 11 men and 9 women (mean ± SD age 58.2±9.5 years) with different malignancies treated with cisplatin in four cycles of chemotherapy (I - IV). Samples 0-4 were taken before, immediately after, in 3, 6 and 24 hours after administering chemotherapy. We detected significant increase of ACR in Sample 2 (p=0.03) and decrease of eGFR in Sample 4 (p=0.03) up to 24 hours after cisplatin administration in the first chemotherapy cycle only. When cumulative effect of cisplatin was assessed, significantly increased values of urine albumin (vs cycle I) were found in Sample 0 (p=0.00058), 1 (p=0.00256), 2 (p=0.00456), 3 (p=0.00006) and 4 (p=0.00319) in cycles II to IV. We found a correlation between values of urine NGAL and urine albumin (r=0.68, p<0.0001). In conclusion, urine albumin was the only measured marker that consistently and statistically significantly increased after cisplatin containing chemotherapy cycles.

Department of Clinical Biochemistry and Hematology Faculty of Medicine in Pilsen Charles University and University Hospital in Pilsen Czech Republic

Zobrazit více v PubMed

CHAKRABORTY S, KAUR S, GUHA S, BATRA SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta. 2012;1826:129–169. doi: 10.1016/j.bbcan.2012.03.008. PubMed DOI PMC

De JONGH FE, Van VEEN RN, VELTMAN SJ, De WIT R, van der BURG MEL, van den BENT MJ, PLANTING AST, GRAVELAND WJ, STOTER G, VERWEIJ J. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer. 2003;88:1199–1206. doi: 10.1038/sj.bjc.6600884. PubMed DOI PMC

DEVARAJAN P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med. 2010;4:265–280. doi: 10.2217/bmm.10.12. PubMed DOI PMC

DROTT C, SVANINGER G, LUNDHOLM K. Increased urinary excretion of cortisol and catecholami-NES in malnourished cancer patients. Ann Surg. 1988;208:645–650. doi: 10.1097/00000658-198811000-00017. PubMed DOI PMC

GASPARI F, CRAVEDI P, MANDALÀ M, PERICO N, DE LEON FR, STUCCHI N, FERRARI S, LABIANCA R, REMUZZI G, RUGGENENTI P. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. Nephron Clin Pract. 2010;115:c154–c160. doi: 10.1159/000312879. PubMed DOI

GAYGISIZ Ü, AYDOGDU M, BADOGLU M, BOYACI N, GÜLLÜ Z, GÜRSEL G. Can admission serum cystatin C level be an early marker subclinical acute kidney injury in critical care patients? Scand J Clin Lab Invest. 2016;76:143–150. doi: 10.3109/00365513.2015.1126854. PubMed DOI

GEORGE B, WEN X, MERCKE N, GOMEZ M, O’BRYANT C, BOWLES DW, HU Y, HOGAN SL, JOY MS, ALEKSUNES LM. Profiling of kidney injury biomarkers in patients receiving cisplatin: Time-dependent changes in the absence of clinical nephrotoxicity. Clin Pharmacol Ther. 2017;101:510–518. doi: 10.1002/cpt.606. PubMed DOI PMC

HAASE M, DEVARAJAN P, HAASE-FIELITZ A, BELLOMO R, CRUZ DN, WAGENER G, KRAWCZESKI CD, KOYNER JL, MURRAY P, ZAPPITELLI M, GOLDSTEIN SL, MAKRIS K, RONCO C, MARTENSSON J, MARTLING C-R, VENGE P, SIEW E, WARE LB, IKIZLER A, MERTENS PR. the outcome of neutrophil gelatinase-associated lipocalin (NGAL)-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011;57:1752–1761. doi: 10.1016/j.jacc.2010.11.051. PubMed DOI PMC

HAASE-FIELITZ A, HAASE M, DEVARAJAN P. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann Clin Biochem. 2014;51:335–351. doi: 10.1177/0004563214521795. PubMed DOI PMC

HEERSPINK HJL, GANSEVOORT RT. Albuminuria Is an appropriate therapeutic target in patients with CKD: The pro view. Clin J Am Soc Nephrol. 2015;10:1079–88. doi: 10.2215/CJN.11511114. PubMed DOI PMC

KIDNEY DISEASE. IMPROVING GLOBAL OUTCOMES (KDIGO) CKD WORK GROUP: KDIGO 2012 CLINICAL PRACTICE GUIDELINE FOR THE EVALUATION AND MANAGEMENT OF CHRONIC KIDNEY DISEASE. Kidney Int. 2013;3:1–150. PubMed

KIM J. Poly(ADP-ribose) polymerase activation induces high mobility group box 1 release from proximal tubular cells during cisplatin nephrotoxicity. Physiol Res. 2016;65:333–340. doi: 10.33549/physiolres.932948. PubMed DOI

KOS J, S̆TABUC B, CIMERMAN N, BRÜNNER N. Serum Cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem. 1998;44:2556–2557. doi: 10.1093/clinchem/44.12.2556. PubMed DOI

LIN HY-H, LEE S-C, LIN S-F, HSIAO H-H, LIU Y-C, YANG W-C, HWANG D-Y, HUNG C-C, CHEN H-C, GUH J-Y. Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatin-induced acute kidney injury better than albuminuria or urinary cystatin C levels. Kaohsiung J Med Sci. 2013;29:304–311. doi: 10.1016/j.kjms.2012.10.004. PubMed DOI PMC

MAGHSOUDI O, MIRJALILI SH, DOLATABADI M, JOSHAGHANI MF, ZAREA M, YAHAGHI E, MOKARIZADEH A. Investigations of renal function using the level of neutrophil gelatinase-associated lipocalin associated with single-dose of cisplatin during chemotherapy. Diagn Pathol. 2015;10:98. doi: 10.1186/s13000-015-0338-5. PubMed DOI PMC

MILLER RP, TADAGAVADI RK, RAMESH G, REEVES WB. Mechanisms of Cisplatin Nephrotoxicity. Toxins. 2010;2:2490–2518. doi: 10.3390/toxins2112490. PubMed DOI PMC

MISHRA J, MA Q, PRADA A, MITSNEFES M, ZAHEDI K, YANG J, BARASCH J, DEVARAJAN P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14:2534–2543. doi: 10.1097/01.ASN.0000088027.54400.C6. PubMed DOI

NICKOLAS TL, BARASCH J, DEVARAJAN P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens. 2008;17:127–132. doi: 10.1097/MNH.0b013e3282f4e525. PubMed DOI

TSIGOU E, PSALLIDA V, DEMPONERAS C, BOUTZOUKA E, BALTOPOULOS G. Role of new biomarkers: functional and structural damage. Crit Care Res Pract. 2013 doi: 10.1155/2013/361078. PubMed DOI PMC

WAIKAR SS, SABBISETTI VS, BONVENTRE JV. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int. 2010;78:486–494. doi: 10.1038/ki.2010.165. PubMed DOI PMC

XU Y, DING Y, LI X, WU X. Cystatin C is a disease-associated protein subject to multiple regulation. Immunol Cell Biol. 2015;93:442–451. doi: 10.1038/icb.2014.121. PubMed DOI PMC